Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Room for manoeuvre when prescribing statins to dyslipidaemic patients on antiretroviral therapy.

Myers J, Rayment M, Sonecha S, Moyle G, Boffito M.

HIV Med. 2012 Mar;13(3):190-2. doi: 10.1111/j.1468-1293.2011.00957.x. No abstract available.

2.

Clinical management considerations for dyslipidemia in HIV-infected individuals.

Kirchner JT.

Postgrad Med. 2012 Jan;124(1):31-40. doi: 10.3810/pgm.2012.01.2515. Review.

PMID:
22314112
3.

Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir.

de Kanter CT, Keuter M, van der Lee MJ, Koopmans PP, Burger DM.

Antivir Ther. 2011;16(3):435-7. doi: 10.3851/IMP1747.

PMID:
21555828
4.

The role of statins in the setting of HIV infection.

Eckard AR, McComsey GA.

Curr HIV/AIDS Rep. 2015 Sep;12(3):305-12. doi: 10.1007/s11904-015-0273-9. Review.

PMID:
26126687
5.

Complications & side effects. Can statins be used as anti-HIV drugs?

[No authors listed]

TreatmentUpdate. 2004 Nov-Dec;16(7):9. No abstract available.

PMID:
17219689
6.

Statins may not affect CD4 response.

Gadd C.

IAPAC Mon. 2006 Feb;12(2):33. No abstract available.

PMID:
17249133
7.

Lipid lowering effects of statins and fibrates in the management of HIV dyslipidemias associated with antiretroviral therapy in HIV clinical practice.

Visnegarwala F, Maldonado M, Sajja P, Minihan JL, Rodriguez-Barradas MC, Ong O, Lahart CJ, Hasan MQ, Balasubramanyam A, White AC Jr.

J Infect. 2004 Nov;49(4):283-90.

PMID:
15474625
9.

Antiretroviral and statin drug-drug interactions.

Ray GM.

Cardiol Rev. 2009 Jan-Feb;17(1):44-7. doi: 10.1097/CRD.0b013e3181903b7f. Review.

PMID:
19092370
10.

Summaries for patients. Response to cholesterol-lowering drugs in patients with and without HIV infection.

[No authors listed]

Ann Intern Med. 2009 Mar 3;150(5):I38. No abstract available.

PMID:
19258553
11.
12.

Statins and natural regulatory T cells in HIV infection.

Mascitelli L, Pezzetta F, Goldstein MR.

HIV Med. 2008 Feb;9(2):131. doi: 10.1111/j.1468-1293.2007.00532.x. No abstract available.

15.

Ezetimibe, a promising lipid-lowering agent for the treatment of dyslipidaemia in HIV-infected patients with poor response to statins.

Negredo E, Moltó J, Puig J, Cinquegrana D, Bonjoch A, Pérez-Alvarez N, López-Blázquez R, Blanco A, Clotet B, Rey-Joly C.

AIDS. 2006 Nov 14;20(17):2159-64.

PMID:
17086055
16.

Factors associated with incomplete virological response to highly active antiretroviral therapy.

Welch K, Morse A, Clark R, Ogbuokiri T.

Clin Infect Dis. 2000 Feb;30(2):407-8. No abstract available.

17.

Are HIV positive patients resistant to statin therapy?

Johns KW, Bennett MT, Bondy GP.

Lipids Health Dis. 2007 Oct 24;6:27.

18.

Evaluation of the anti-HIV activity of statins.

Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, Clotet B, Esté JA.

AIDS. 2005 Oct 14;19(15):1697-700.

PMID:
16184043
19.

Treatment of AIDS and HIV-related conditions--2002: antiretroviral therapy.

Goldschrnidt RH, Dong BJ.

J Am Board Fam Pract. 2002 Jul-Aug;15(4):319-31. No abstract available.

20.

Treating antiretroviral-induced dyslipidemia in HIV-infected adults.

Scordo KA.

Nurse Pract. 2010 Jul;35(7):32-7; quiz 37-8. doi: 10.1097/01.NPR.0000383658.60403.6b. No abstract available.

PMID:
20555242
Items per page

Supplemental Content

Write to the Help Desk